<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01798628</url>
  </required_header>
  <id_info>
    <org_study_id>CR016960</org_study_id>
    <secondary_id>COU-AA-009</secondary_id>
    <nct_id>NCT01798628</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male Patients</brief_title>
  <official_title>A Phase 1, Single Dose, Open-Label, Three-Period, Crossover Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cougar Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cougar Biotechnology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of food on the pharmacokinetics (how the&#xD;
      drug concentrations change over time) of abiraterone acetate 1000 mg when administered as a&#xD;
      single dose in healthy male volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label (identity of assigned study drug will be known), randomized (treatment&#xD;
      sequences will be assigned by chance) study of a single dose of abiraterone acetate 1000 mg&#xD;
      administered orally (by mouth) in approximately 36 healthy male participants under fasted and&#xD;
      fed conditions. Three doses of abiraterone acetate will be administered with a 7-day washout&#xD;
      period between each dose. The total study duration for each participant will be 21 days.&#xD;
      Participants will be randomized to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB,&#xD;
      CBA): Treatment A = abiraterone acetate 1000 mg administered after a high-fat meal; Treatment&#xD;
      B = abiraterone acetate 1000 mg administered after a low-fat meal; Treatment C = abiraterone&#xD;
      acetate 1000 mg administered in the fasted state. No food will be ingested for 4 hours&#xD;
      post-dose. Participants will be confined at the clinical research unit from the day prior to&#xD;
      dosing until clinic discharge on the day following dosing in each treatment period. Serial&#xD;
      pharmacokinetic samples will be collected and safety will be monitored throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed concentration of abiraterone</measure>
    <time_frame>Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum concentration of abiraterone</measure>
    <time_frame>Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time 0 to the last measurable concentration of abiraterone</measure>
    <time_frame>Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve extrapolated to infinity of abiraterone</measure>
    <time_frame>Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent plasma terminal elimination rate constant of abiraterone</measure>
    <time_frame>Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination half-life of abiraterone</measure>
    <time_frame>Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants affected by an adverse event</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Sequence ABC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence ACB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence BAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence BCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence CAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence CBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A: abiraterone acetate</intervention_name>
    <description>1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal</description>
    <arm_group_label>Sequence ABC</arm_group_label>
    <arm_group_label>Sequence ACB</arm_group_label>
    <arm_group_label>Sequence BAC</arm_group_label>
    <arm_group_label>Sequence BCA</arm_group_label>
    <arm_group_label>Sequence CAB</arm_group_label>
    <arm_group_label>Sequence CBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B: abiraterone acetate</intervention_name>
    <description>1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal</description>
    <arm_group_label>Sequence ABC</arm_group_label>
    <arm_group_label>Sequence ACB</arm_group_label>
    <arm_group_label>Sequence BAC</arm_group_label>
    <arm_group_label>Sequence BCA</arm_group_label>
    <arm_group_label>Sequence CAB</arm_group_label>
    <arm_group_label>Sequence CBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C: abiraterone acetate</intervention_name>
    <description>1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state</description>
    <arm_group_label>Sequence ABC</arm_group_label>
    <arm_group_label>Sequence ACB</arm_group_label>
    <arm_group_label>Sequence BAC</arm_group_label>
    <arm_group_label>Sequence BCA</arm_group_label>
    <arm_group_label>Sequence CAB</arm_group_label>
    <arm_group_label>Sequence CBA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  In good general health as determined by no clinically significant findings on medical&#xD;
             history, physical examination, vital signs, 12-lead electrocardiogram, and clinical&#xD;
             laboratory measurements&#xD;
&#xD;
          -  Body mass index within 18 kg/m2 to 32 kg/m2, inclusive&#xD;
&#xD;
          -  Non-tobacco users&#xD;
&#xD;
          -  Clinical laboratory values within protocol-defined parameters&#xD;
&#xD;
          -  Negative hepatitis panel (including hepatitis B surface antigen [HBsAg] and hepatitis&#xD;
             C virus antibody [anti-HCV]),and negative human immunodeficiency virus (HIV) antibody&#xD;
             screens&#xD;
&#xD;
          -  Negative test for selected drugs of abuse&#xD;
&#xD;
          -  Agrees to protocol-defined use of effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant history or manifestation of any significant metabolic, allergic,&#xD;
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological or psychiatric disorder, as determined by the Principal&#xD;
             Investigator&#xD;
&#xD;
          -  History or presence of an abnormal electrocardiogram&#xD;
&#xD;
          -  History of stomach or intestinal surgery resection that would potentially alter&#xD;
             absorption and/or excretion of orally administered drugs&#xD;
&#xD;
          -  Screening serum total testosterone of &lt;200 ng/dL&#xD;
&#xD;
          -  History of hypersensitivity reaction to the study drug, related compounds or&#xD;
             excipients used in the formulation&#xD;
&#xD;
          -  Receipt of an investigational drug within 5 half-lives or 30 days prior to Day -1,&#xD;
             whichever is longer&#xD;
&#xD;
          -  Abnormal diet during the 30 days prior to Day 1&#xD;
&#xD;
          -  Donation of blood or significant loss of blood within 56 days or plasma within 14 days&#xD;
             prior to Day -1&#xD;
&#xD;
          -  Planned donation of blood or plasma from Screening through Study Completion, Day 21&#xD;
&#xD;
          -  Receipt of blood products within 2 months prior to Day 1&#xD;
&#xD;
          -  History of protocol-defined alcohol abuse&#xD;
&#xD;
          -  Known or suspected use of illicit drugs within the last year&#xD;
&#xD;
          -  Use of any medication on a chronic basis&#xD;
&#xD;
          -  Use of any prescription medications/products or over-the-counter non-prescription&#xD;
             preparations within 5 half-lives or 7 days prior to Day -1 unless deemed acceptable by&#xD;
             the Sponsor&#xD;
&#xD;
          -  Consumption of alcohol-containing foods or beverages within 24 hours prior to the&#xD;
             first Check-in (Day -1)&#xD;
&#xD;
          -  Unwillingness to abstain from alcohol consumption from Day -1 to Study Completion&#xD;
             (Day21)&#xD;
&#xD;
          -  Consumption of caffeine-containing or grapefruit-containing foods or beverages within&#xD;
             72 hours prior to Day -1&#xD;
&#xD;
          -  Unwillingness to abstain from caffeine-containing or grapefruit-containing foods or&#xD;
             beverages from Day -1 through Study Completion (Day21)&#xD;
&#xD;
          -  Presence of sexual dysfunction or any medical condition that would affect sexual&#xD;
             function&#xD;
&#xD;
          -  Unwillingness to refrain from strenuous exercise from 48 hours prior to Day -1 and for&#xD;
             the duration of the study&#xD;
&#xD;
          -  Presence of any condition that, in the opinion of the Investigator, would limit the&#xD;
             participant's ability to complete and/or participate in this study&#xD;
&#xD;
          -  Unwillingness to refrain from using any tobacco or nicotine-containing products during&#xD;
             screening and throughout the study to Study Completion (Day 21)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cougar Biotechnology, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Cougar Biotechnology, Inc.</affiliation>
  </overall_official>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>October 22, 2012</study_first_submitted>
  <study_first_submitted_qc>February 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2013</study_first_posted>
  <last_update_submitted>February 22, 2013</last_update_submitted>
  <last_update_submitted_qc>February 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>Abiraterone acetate</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

